YOUR SEARCH FOR Text 260 RESULTS
231 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
232 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
233 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
234 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
235 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
236 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
237 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
238 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
239 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
240 of Total
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a